YOLFTbeta
Oculis Holding AG Ordinary shares

Oculis Holding AG Ordinary shares

OCS · NASDAQ · Healthcare / Biotechnology

7.64USD+0.14 (+1.87%)

Price History

Full chart

Market Stats

Previous Close7.50
Open7.51
Day Range7.28 – 7.68
52-Week Range9.00 – 34.48
Volume183.97K
Market Cap503.08M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.67
Dividend Yield0.00%
Beta0.23
50-Day Avg11.67
200-Day Avg20.35

About

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Riad Sherif M.B.A., M.D.
  • Employees60
  • HeadquartersBahnhofstrasse 20, Zug, Switzerland, 6300, USA
  • Websitehttps://oculis.com

Leadership

  • Dr. Riad Sherif M.B.A., M.D.CEO & Director · b. 1968
  • Ms. Sylvia CheungChief Financial Officer · b. 1975
  • Ms. Gudrun Bachmann Ph.D.Chief Technology Officer
  • Dr. Ramin Tadayoni M.D., Ph.D.Chief Scientific Officer
  • Ms. Katie KazemChief Legal Officer
  • Ms. Virginia R. DeanChief Human Resources Officer · b. 1966
  • Mr. Páll Ragnar JóhannessonChief Business Officer · b. 1982
  • Ms. Rebecca Weil Ph.D.Chief Commercial Officer
  • Dr. Snehal Shah Pharm.D.President of Research & Development
  • Dr. Sharon Klier M.D., M.P.H.Chief Development Officer

Financials

Income Statement

Currency: CHF2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue993.00K960.00K912.00K883.00K686.00K0
Growth (%)--3.32%-5.00%-3.18%-22.31%-100.00%
Cost of Revenue9.34M9.57M22.22M29.25M52.08M-
Gross Profit-8.34M-8.61M-21.31M-28.36M-51.40M-
Gross Margin-840.28%-896.67%-2336.84%-3212.23%-7492.27%-
Operating Expense3.99M4.62M11.06M52.35M21.81M-
Operating Income-12.34M-13.23M-32.38M-80.71M-73.20M-79.15M
Operating Margin-1242.30%-1378.33%-3550.00%-9140.88%-10671.14%-
EBITDA-12.10M-13.17M-31.90M-87.09M-85.53M-93.37M
EBITDA Margin-1218.23%-1371.77%-3498.03%-9863.31%-12468.08%-
Net Income-14.87M-18.55M-38.70M-88.80M-85.78M-94.51M
Net Income Margin-1497.78%-1932.50%-4243.20%-10056.85%-12503.94%-
R&D9.34M9.57M22.22M29.25M52.08M54.52M
R&D as % of Total Revenue940.28%996.67%2436.84%3312.23%7592.27%-
Interest Expense2.63M5.12M6.44M1.46M639.00K795.55K
Interest Expense % of Total Revenue264.65%533.33%706.36%165.72%93.15%-

Balance Sheet

Currency: CHF2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets16.38M58.04M37.06M114.35M120.35M236.23M
Total Liabilities60.04M119.00M135.05M20.63M46.97M39.94M
Total Equity-43.65M-60.95M-97.99M93.73M73.38M196.29M
Cash4.95M46.28M19.79M38.33M27.71M81.42M
Total Debt54.81M114.27M123.08M605.00K1.18M2.32M
Net Debt49.86M68.00M103.30M-37.72M-26.53M-79.11M

Cash Flow

Currency: CHF2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-12.03M-13.82M-25.07M-53.84M-47.50M-62.22M
Investing Cash Flow-19.00K-28.00K-3.55M-54.21M-17.56M-59.38M
Financing Cash Flow4.86M55.19M1.71M129.67M54.03M178.60M
Capital Expenditure19.00K28.00K3.55M48.00K230.00K287.47K
Free Cash Flow-12.05M-13.85M-28.62M-53.89M-47.73M-62.51M
Dividends Paid---000
FCF to OCF100.16%100.20%114.15%100.09%100.48%100.46%
Dividend Paid to FCF---0.00%0.00%0.00%

Earnings

Report DateJun 22, 2021Aug 18, 2021Nov 23, 2021Mar 31, 2022May 16, 2022Aug 15, 2022Nov 14, 2022Feb 28, 2023Mar 31, 2023Aug 29, 2023Nov 15, 2023Mar 18, 2024May 9, 2024Aug 27, 2024Nov 7, 2024Mar 11, 2025May 8, 2025Aug 21, 2025Nov 10, 2025Mar 4, 2026May 11, 2026Aug 6, 2026Nov 9, 2026
EPS Estimate0.000.000.000.000.000.000.00--0.33-0.29-0.25-0.39-0.40-0.37-0.42-0.43-0.40-0.45-0.41-0.41-0.41-0.48-0.49
EPS Actual0.020.040.07-0.030.110.01-0.02-0.06-1.51-0.38-0.34-0.34-0.44-0.51-0.48-0.67-0.69-0.49-0.32-0.42-0.49-0.20-
Surprise---------357.58%-31.03%-36.00%12.82%-10.00%-36.58%-14.29%-55.81%-72.50%-8.89%21.95%-2.14%-19.51%58.33%-
Timing---------Pre-marketPre-marketPre-market--Pre-market-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap503.08M
Enterprise Value278.59M
Trailing P/E0.00
Forward P/E0.00
Price / Sales428.89
Price / Book2.07
EPS-1.67
Book Value4.32
Revenue (TTM)1.17M
Gross Profit (TTM)-55.56M
EBITDA-85.98M
Profit Margin0.00%
Operating Margin-7602.58%
Return on Equity-43.70%
Return on Assets-24.95%
Shares Outstanding55.53M
Shares Float52.41M
Beta0.23
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 7 analystsTarget 36.51
  • Strong Buy
    5
  • Buy
    2

Ownership Breakdown

Institutions
47.55%
Insiders
3.53%
Retail / Other
48.92%

Top Institutional Holders

  • EQT Fund Management S.à r.l.
    6.95M11.29%
  • Gildi - lifeyrissjodur
    2.43M3.95%
  • Aberdeen Group PLC
    2.16M3.51%
  • Millennium Management LLC
    2.04M3.32%
  • Pivotal bioVenture Partners Investment Advisor LLC
    1.51M2.45%
  • Citadel Advisors Llc
    987.20K1.60%
  • Perceptive Advisors LLC
    808.83K1.31%
  • Saturn V Capital Management LLC
    684.88K1.11%
  • SR ONE CAPITAL MANAGEMENT, LP
    641.02K1.04%
  • Wellington Management Company LLP
    540.06K0.88%
  • Partner Fund Management LP
    436.04K0.71%
  • SYQUANT CAPITAL SAS
    375.00K0.61%
  • Alyeska Investment Group, L.P.
    331.33K0.54%

Top Fund Holders

  • HBM Healthcare Investments AG Ord
    993.83K1.61%
  • abrdn Healthcare Investors
    855.88K1.39%
  • abrdn Healthcare Opportunities
    717.34K1.16%
  • Franklin Biotechnology Discv A(acc)USD
    582.38K0.95%
  • abrdn World Healthcare
    487.87K0.79%
  • abrdn Life Sciences Investors
    419.14K0.68%
  • Stefnir Icelandic Growth
    326.65K0.53%